Wells Fargo
CLDI icon

Wells Fargo’s Calidi Biotherapeutics CLDI Stock Holding History

Wells Fargo’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$79 – 6987
2024
Q1 		$79 Hold
1
– – ﹤0.01% 6720
2023
Q4 		$208 Buy
+1
New +$268 ﹤0.01% 6596

Other funds holding CLDI

RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $517M AUM 16.68% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $559M AUM 19.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Wells Fargo's CLDI Position: Q2 2024 in Review

Wells Fargo sold out of Calidi Biotherapeutics (CLDI) in Q2 2024, closing a stake of 1 share — an estimated $79 sold.

Wells Fargo first reported a position in CLDI in Q4 2023 and held it in 2 quarters. The position peaked at $208 in Q4 2023. 31 funds tracked by Wall St. Rank hold CLDI as of Q2 2024.

  • Wells Fargo reported no remaining Calidi Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • Wells Fargo sold 1 Calidi Biotherapeutics share in Q2 2024, an estimated $79.
  • Wells Fargo first reported a position in Calidi Biotherapeutics in Q4 2023 and held it in 2 quarters.
  • Wells Fargo's Calidi Biotherapeutics position peaked at $208 in Q4 2023.
  • 31 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.